Sana Biotechnology, Inc.于2018年7月13日在特拉华州注册成立。该公司正在开发离体和体内细胞工程平台，以彻底改变一系列尚未满足治疗需求的治疗领域，包括肿瘤学、糖尿病、中枢神经系统疾病、心血管疾病和遗传疾病等。预计该公司的第一个项目，即CD19靶向异体嵌合抗原受体（CAR）T（SC291）项目的临床数据将在2023年发布。该公司还在开发细胞工程平台方面取得进展，并通过临床前开发推进候选产品，目标是在2023年及以后提交多个研究性新药。
董事
名称
职位
Hans Bishop
Chairman of the Board
Richard C. Mulligan
Head of SanaX and Executive Vice-Chairman
Steven D. Harr
President, Chief Executive Officer, and Director
Alise S. Reicin
Director
Douglas Cole
Director
Geoffrey von Maltzahn
Director
Joshua H. Bilenker
Director
Mary Agnes Wilderotter
Director
Michelle Seitz
Director
Patrick Yang
Director
Robert Taylor NELSEN
Director
股东
名称
职位
Steven D. Harr
President, Chief Executive Officer, and Director
Christian Hordo
Senior Vice President, Chief Business Officer
Nathan Hardy
Senior Vice President, Chief Financial Officer
James J. MacDonald
Executive Vice President, General Counsel, and Corporate Secretary
Richard C. Mulligan
Head of SanaX and Executive Vice-Chairman
Sunil Agarwal
Executive Vice President, Head of Development and Chief Medical Officer